David Epstein, Evelo chairman (Flagship Pioneering)
December 9, 2020 10:56 AM ESTUpdated 02:17 PM
R&D

Lit­tle Evelo sees big promise in its first cut of da­ta from a tiny study on atopic der­mati­tis

John Carroll

Editor & Founder

Any­one putting to­geth­er an ear­ly-stage tri­al in­volv­ing 24 pa­tients with a big-mar­ket dis­ease like atopic der­mati­tis wants to know one thing: Do they have a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times